High-dose Semaglutide Injection Approved by the European Union

Xinjing Times reported (by reporter Wang Kala): Recently, the European Commission approved a new 7.2 mg once-a-week maintenance dose of Wegovy (semaglutide injection) for adult patients with obesity. This approval gives doctors a new treatment option to help adult patients who still need additional weight loss after using the 2.4 mg dose. The approval decision was based on a positive review opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency on December 12, 2025.

This approval means that, in the EU, physicians can now prescribe the 7.2 mg dose—i.e., a single injection of three 2.4 mg pens—still administered once per week. Novo Nordisk has submitted an application to market the 7.2 mg single-dose injection pen to the EU; if approved, it is expected to be launched this year. This also means that, in the EU, adult patients with obesity who use Wegovy 2.4 mg (for at least 4 weeks) and need greater weight loss while maintaining muscle function can directly step up to the 7.2 mg dose.

Wegovy 7.2 mg has already been approved and launched in the UK, and in the United States the Food and Drug Administration (FDA) and multiple other countries’ regulatory bodies are currently reviewing its registration applications.

Research results show that: In two clinical studies, STEP UP and STEP UP T2D, which enrolled adult obesity patients with or without type 2 diabetes, participants receiving once-a-week treatment with the 7.2 mg dose in combination with lifestyle interventions achieved weight-loss outcomes significantly greater than those receiving placebo treatment.

At present, Wegovy injection 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and the newly added 7.2 mg dose have been launched within the EU. Wegovy tablets have been launched in the United States, and EU approval is underway.